News & Updates
Filter by Specialty:
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.
Fosaprepitant dosing frequency makes no difference in CCRT-induced nausea, vomiting prevention
09 Aug 2023
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.
Second-line avelumab works against dMMR/MSI metastatic colorectal cancer
09 Aug 2023
Uncomplicated UTI: Choosing antibiotics based on resistance rates helps prevent treatment failure
In the treatment of individuals with uncomplicated urinary tract infection (UTI), the use of antibiotics with lower reported resistance rates such as amoxicillin-clavulanate and nitrofurantoin (AC + N) lowers the rate of treatment failure, as shown in a study from Singapore.
Uncomplicated UTI: Choosing antibiotics based on resistance rates helps prevent treatment failure
08 Aug 2023
GLP-1 RA, with or without SGLT2 inhibitors, prevents cardiac events in T2D
Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1 RA) albiglutide results in fewer cardiovascular events, irrespective of sodium-glucose cotransporter-2 (SGLT2) inhibitor use, among patients with type 2 diabetes (T2D) and cardiovascular disease, according to the post hoc analysis of Harmony Outcomes*.
GLP-1 RA, with or without SGLT2 inhibitors, prevents cardiac events in T2D
08 Aug 2023
Large cohort study on diabetes launched
The Seremban Diabetes (SeDia) Cohort Study, the first large-scale diabetes study of its kind in Malaysia has been launched by the Ministry of Health Malaysia (MOH) and International Medical University (IMU).